Axicabtagene ciloleucel is in clinical development as treatment for adult patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL). In NHL, the affected lymphocytes start to multiply in an abnormal way and begin to collect in certain parts of the body, such as the lymph nodes. Indolent, or low grade NHL tends to grow very slowly. Types of low-grade NHL include follicular and marginal zone lymphoma. Relapse means that the lymphoma has come back after going into complete remission. Lymphoma that does not go into remission with treatment is known as refractory lymphoma. Treatment options for relapsed/refractory indolent NHL after two priori treatments are limited.
Axicabtagene ciloleucel is an advanced therapy that contains the patient’s own white blood cell (T-cells) that have been modified genetically in the laboratory so that they make a protein called chimeric antigen receptor (CAR). The CAR T-cells attach to another protein on the surface of cancer cells and causing the cells to die. If licensed, axicabtagene ciloleucel will offer an additional treatment for patients with relapsed/refractory indolent NHL including follicular and marginal zone lymphoma.
Nivolumab in combination with cisplatin and fluorouracil is in clinical development for patients with unresectable, advanced, recurrent or metastatic oesophageal squamous cell cancer cell carcinoma. Advanced oesophageal cancer begins in the food pipe and spreads to other parts of the body. Squamous cell cancers develop from the cells that make up the inner lining of the oesophagus. Symptoms include difficulty swallowing, persistent acid indigestion or heartburn, weight loss, pain in the throat, and chronic cough. Lifestyle factors are attributed to most oesophageal cancers, including smoking and being overweight.